European regimen accelerator for Tuberculosis [1]
In short
Worldwide, Tuberculosis [2] (TB) is one of the top 10 causes of death and the leading cause from a single infectious agent (above HIV/AIDS). TB can be drug-resistant, which makes it the largest single contributor to antimicrobial resistance (AMR) and remains a public health crisis and a health security threat. TB is a disease where societal, public health and biomedical industry competitiveness align with World Health Organization (WHO) goals. There is an urgent need of new measurements and compounds against this disease.
Project description
This project [3] tests a collection of anti-Tuberculosis compounds in various stages of development. The challenge is to develop new, active anti-TB compounds and combinations with favorable properties for production at low cost, without clinically relevant interactions between drugs and cross-resistance with other TB drugs. These regimens will be compatible with drugs used to treat common comorbidities, such as HIV-AIDS and diabetes.
Sciensano is implicated in the ‘In vivo profiling’. The objective is the establishment and use of various murine models to test new anti-TB drug candidates. Drug candidates will be assayed
singly or in combination, in comparison to reference TB drugs, using different M. tuberculosis strains and/or infection routes. Data generation and experimental protocols will be optimized and standardized. Subsequently, promising regimens will move to non-human primate (NHP) models for evaluation.
Sciensano's project investigator(s):
Service(s) working on this project
Partners
